Since the first report of type 1 melatonin receptor (Mt1) and β-secretase 1 (Bace1) for the regulation of Aβ production, targeting Mt1 and Bace1 has been considered a powerful therapeutic approach for Alzheimer’s disease [167]. The gene discussed is BACE1; the disease is early-onset autosomal dominant Alzheimer disease.